Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Viridian Therapeutics, Inc. (VRDN) will present at the 42nd Annual J.P. Morgan Healthcare Conference, discussing corporate priorities and potential best-in-class medicines for serious and rare diseases.

WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that its President and Chief Executive Officer, Steve Mahoney, will present an overview of the company along with its upcoming corporate priorities at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 7:30am PT / 10:30am ET in San Francisco, California. In addition, the company will webcast the question-and-answer breakout session immediately following its presentation at 7:50am PT / 10:50am ET.

The live webcast of the presentation and breakout session can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. A replay of the webcast will be available on the company’s website following the event.

About Viridian Therapeutics

Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a best-in-class IV therapy followed by VRDN-003 as a first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Viridian is also developing additional preclinical assets in autoimmune and rare diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.

Source: Viridian Therapeutics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240104648163/en/

Louisa Stone, 617-272-4604

Manager, Investor Relations

IR@viridiantherapeutics.com

Source: Viridian Therapeutics, Inc.

FAQ

What is Viridian Therapeutics, Inc. (VRDN) presenting at the 42nd Annual J.P. Morgan Healthcare Conference?

Viridian Therapeutics, Inc. (VRDN) will present an overview of the company and its upcoming corporate priorities.

When will the presentation take place?

The presentation will take place on Thursday, January 11, 2024, at 7:30am PT / 10:30am ET.

Where can the webcast of the presentation and breakout session be accessed?

The webcast can be accessed under 'Events and Presentations' on the Investors section of the Viridian website at viridiantherapeutics.com.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available on the company’s website following the event.